ImmunityBio (NASDAQ:IBRX) versus Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head Review

Monte Rosa Therapeutics (NASDAQ:GLUE) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Monte Rosa Therapeutics and ImmunityBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	2	8	1	2.75
ImmunityBio	1	0	6	0	2.71

Monte Rosa Therapeutics currently has a consensus price target of $26.67, suggesting a potential upside of 171.00%. ImmunityBio has a consensus price target of $16.00, suggesting a potential upside of 61.45%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Monte Rosa Therapeutics is more favorable than ImmunityBio.

Risk and Volatility

Monte Rosa Therapeutics has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.

Institutional and Insider Ownership

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Monte Rosa Therapeutics and ImmunityBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
ImmunityBio	-598.55%	N/A	-51.65%

Earnings and Valuation

This table compares Monte Rosa Therapeutics and ImmunityBio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67 million	6.79	-$38.63 million	($1.76)	-5.59
ImmunityBio	$113.29 million	92.71	-$351.40 million	($0.97)	-10.22

Monte Rosa Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Monte Rosa Therapeutics beats ImmunityBio on 11 of the 15 factors compared between the two stocks.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About ImmunityBio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.